Idiopathic Hypersomnia Clinical Trials 2024

What are the top hospitals conducting idiopathic hypersomnia research?

When it comes to the study of idiopathic hypersomnia, several hospitals are at the forefront of clinical trials, offering hope and potential breakthroughs for those affected by this rare sleep disorder. Sleep Medicine Specialists of California in San Ramon leads the way with three active trials focused on idiopathic hypersomnia. Since their first recorded trial in 2018, they have been committed to exploring new treatment options and understanding this complex condition. Stanford University in Redwood City also plays a crucial role in advancing our knowledge of idiopathic hypersomnia, with two ongoing trials and a history that began with their inaugural trial in 2022.

Further contributing to research efforts is Intrepid Research located in Cincinnati. Their dedication can be seen through two current active clinical trials addressing idiopathic hypersomnia and an overall record of three completed studies since they embarked on their first trial related to this condition back in 2018. Bogan Sleep Consultants based out of Columbia has also made significant contributions, conducting two ongoing clinical investigations alongside their accomplishments from another grand total count of having conducted three previous research programs which highlight endeavors initiated only as recently as 2022.

Meanwhile, Santa Monica Clinical Trials located within sunny Santa Monica stands strong with its commitment towards better understanding and treating idiopathic hypersomnia through multiple fronts; boasting not only two currently ongoing clinical tests but also an impressive track record consisting parallelly held experimental endeavours numbering up till three previously conducted studies dating all the way back towards inception years starting from around just ten years ago during 2018.

These hospitals stand as beacons of hope for individuals living with idiopathic hypersomnia, showcasing the collaborative effort put forth by medical professionals dedicated to studying this challenging condition. Through these pioneering clinical trials across multiple locations nationwide is how we inch closer towards unlocking answers providing effective treatments for countless patients suffering worldwide

Which are the best cities for idiopathic hypersomnia clinical trials?

In the realm of idiopathic hypersomnia clinical trials, several cities emerge as prominent hubs for research and investigation. Miami, Florida takes the lead with 6 ongoing trials exploring treatments like Experimental: SDX, pitolisant, and Subject Receives BTD001 first. Following closely behind is Atlanta, Georgia with 5 active studies investigating interventions such as Experimental: SDX, pitolisant, and Clarithromycin. Additionally, Chevy Chase in Maryland and Newton in Massachusetts both offer favorable environments for this research field with 4 active trials each focusing on treatment options like pitolisant and Experimental: SDX. Lastly, Redwood City in California also contributes to advancements in idiopathic hypersomnia management through its 3 ongoing studies examining Low Sodium Oxybate for Idiopathic Hypersomnia alongside experimental interventions like SDX and pitolisant. These cities collectively provide valuable opportunities for individuals affected by idiopathic hypersomnia to participate in cutting-edge clinical trials that may enhance understanding of the condition while paving the way towards improved care strategies.

Which are the top treatments for idiopathic hypersomnia being explored in clinical trials?

In the realm of idiopathic hypersomnia, clinical trials are paving the way for potential breakthroughs in treatment. Pitolisant and clarithromycin have emerged as leading contenders in these trials, each showing promise in addressing this debilitating condition. Pitolisant, introduced recently in 2022, is currently undergoing an active trial specifically focused on idiopathic hypersomnia. Similarly, clarithromycin offers hope with its own ongoing trial dedicated to exploring its effectiveness for this disorder since being listed in 2019. As researchers delve deeper into these treatments, they offer renewed optimism for individuals living with idiopathic hypersomnia across the globe.

What are the most recent clinical trials for idiopathic hypersomnia?

Exciting progress is being made in the field of idiopathic hypersomnia, with recent clinical trials exploring potential treatment options. Low sodium oxybate has shown promise in Phase 4 trials for managing symptoms of idiopathic hypersomnia. Additionally, an experimental drug called SDX is currently undergoing Phase 2 testing to evaluate its effectiveness in treating this condition. Another ongoing trial focuses on the use of pitolisant, which has entered Phase 3 and holds potential as a therapeutic option for patients with idiopathic hypersomnia. These developments offer hope for improved management and quality of life for individuals affected by this disorder.

What idiopathic hypersomnia clinical trials were recently completed?

Emory University recently concluded a clinical trial investigating the efficacy of Amphetamine-Dextroamphetamine in treating idiopathic hypersomnia. The completed trial, which ended in April 2019, sheds light on potential treatment options for this challenging sleep disorder. This notable development highlights the commitment of researchers to further our understanding and management of idiopathic hypersomnia, offering hope for individuals affected by this condition.